OPHTHALMIC FORMULATIONS AND PROCESSES FOR THEIR PREPARATION

• US 20130065888A1
• Filed: 08/14/2012
• Published: 03/14/2013
• Est. Priority Date: 08/15/2011
• Status: Abandoned Application

• Current Assignee: Teva Pharmaceuticals USA, Inc. (Teva Pharmaceutical Industries Limited)
• Original Assignee: Biserka Cetina-Cizmek
• Inventors: Tunjic, Iva, CETINA-CIZMEK, Biserka, Bracko, Danka, Miocic, Sandra
• Application Number:
  US13/585,379
• Publication Number:
  US 20130065888A1
• Time in Patent Office: Days
• US Class Current: 514/226.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/498 Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 31/542 ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

The invention relates to a process for preparing ophthalmic formulations and to formulations containing a suspension of an ophthalmic drug in an aqueous vehicle. The invention further relates to the production of stable ophthalmic formulations that have a minimal propensity to form drug aggregates.

Claims

1. A process for preparing an ophthalmic formulation for topical application comprising:

(i) an ophthalmic drug,

(ii) at least one wetting agent, and

(iii) an aqueous vehicle

wherein the ophthalmic drug is in aqueous suspension in the formulation, said process comprising;

(a) subjecting a suspension of the ophthalmic drug in an aqueous solution of wetting agent to high pressure homogenization, and

(b) combining the mixture in step (a) with the aqueous vehicle.

2. A process according to claim 1 wherein step (a) comprises microfluidization or piston-gap homogenization.

3. A process according to claim 1 or claim 2 wherein the high pressure homogenization is conducted under pressures and/or number of cycles so as to effect deagglomeration of drug particle aggregates without a significant reduction in particle size of the drug particles.

8. A process according to claim 1 wherein the suspension of the ophthalmic drug in the aqueous solution of wetting agent is provided by combining a sterile drug with a sterile aqueous solution of wetting agent.

11. A process according to claim 1 wherein the suspension of the ophthalmic drug in the aqueous solution of wetting agent is sterilized prior to high pressure homogenization.

12. A process according to claim 1 wherein the aqueous vehicle is obtained by:

(i) preparing an aqueous slurry containing an ophthalmically acceptable excipient selected from the group consisting of a chelating agent, preservative, tonicity agent, viscosity/suspending agent, and optionally a buffer, or a mixture thereof,

(ii) adjusting the aqueous slurry to an ophthalmically acceptable pH, and

(iii) sterilizing the slurry.

13. A process according to claim 1 wherein the ophthalmic drug is selected from the group consisting of a prostaglandin, carbonic anhydrase inhibitor, α

-adrenergic agonist, non-steroidal anti-inflammatory, anti-fungal agent, antibiotic, corticosteroid, beta-blocker, or a combination thereof.

17. A process according to claim 1 wherein the ophthalmic drug has been micronized prior to step (a).

20. A process according to claim 1 wherein the wetting agent is selected from the group consisting of polyoxypropylene-polyoxyethylene block copolymers (poloxamers), polyethoxylated ethers of castor oils, polyoxyethylenated sorbitan esters (polysorbates), polymers of oxyethylated octyl phenol (Tyloxapol), polyoxyl 40 stearate, fatty acid glycol esters, fatty acid glyceryl esters, sucrose fatty esters, polyoxyethylene fatty esters, and mixtures thereof.

34. A process according to claim 1 wherein the formulation is substantially free of drug particles having a particle size of over 10 μ

m.

35. A process according to claim 1 wherein the formulation contains less than 0.02% by weight of drug particles having a particle size of over 10 μ

m.

36. A process according to claim 1 containing no detectable drug particles having a particle size of over 10 μ

m.

37. A process according to claim 1 wherein the formulation is substantially free of drug particles having a particle size of 10 μ

m or more following shaking the formulation at an amplitude of 90/min for 24 hours at room temperature.

38. A process according to claim 1 having less than 0.02% by weight of drug particles having a particle size of 10 μ

m or more following shaking the formulation at an amplitude of 90/min for 24 hours at room temperature.

41. An ophthalmic formulation obtainable by the process according to claim 1.

4-7. -7. (canceled)

9-10. -10. (canceled)

14. A process according to 1 claim wherein the ophthalmic drug is selected from the group consisting of brimonidine, brinzolamide, dorzolamide, natamycin, ofloxacin, bimatoprost, travoprost, latanoprost, nepafenac, ketoconazole, fluconazole, voriconazole, hydrocortisone, prednisolone, dexamethasone, timolol, levobunolol, betaxolol, or pharmaceutically acceptable salts, and combinations thereof.

15-16. -16. (canceled)

18-19. -19. (canceled)

21-33. -33. (canceled)

39-40. -40. (canceled)

42. An ophthalmic formulation for topical application comprising:

(i) an ophthalmic drug,

(ii) at least one wetting agent, and

(iii) an aqueous vehicle

wherein the ophthalmic drug is in aqueous suspension in the formulation, and the formulation is substantially free of drug particles having a particle size of over 10 μ

m.

43-50. -50. (canceled)

51. A method of preventing the formation of drug aggregates in an ophthalmic formulation containing an ophthalmic drug suspended in an aqueous vehicle containing at least one wetting agent by the use of high pressure homogenization.

52. The method according to claim 51 wherein the drug is a carbonic anhydrase inhibitor selected from brinzolamide or dorzolamide, or pharmaceutically acceptable salts thereof.